After finishing at $0.71 in the prior trading day, DermTech Inc (NASDAQ: DMTK) closed at $0.70, down -0.99%. In other words, the price has decreased by -$0.0070 from its previous closing price. On the day, 162971 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of DMTK by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.52 and its Current Ratio is at 4.59. In the meantime, Its Debt-to-Equity ratio is 0.95 whereas as Long-Term Debt/Eq ratio is at 0.90.
On June 14, 2022, BTIG Research reiterated its Buy rating and also upped its target price recommendation from $38 to $19.
On January 07, 2022, Stephens started tracking the stock assigning a Overweight rating and target price of $26.Stephens initiated its Overweight rating on January 07, 2022, with a $26 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 11 ’23 when Sun Kevin M sold 447 shares for $1.45 per share. The transaction valued at 648 led to the insider holds 277,499 shares of the business.
Ibarra Claudia sold 331 shares of DMTK for $480 on Dec 11 ’23. The Chief Operating Officer now owns 193,547 shares after completing the transaction at $1.45 per share. On Dec 08 ’23, another insider, Ibarra Claudia, who serves as the Chief Operating Officer of the company, sold 2,607 shares for $1.41 each. As a result, the insider received 3,676 and left with 193,878 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DMTK now has a Market Capitalization of 24.06M and an Enterprise Value of 22.59M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.59 while its Price-to-Book (P/B) ratio in mrq is 0.42. Its current Enterprise Value per Revenue stands at 1.48 whereas that against EBITDA is -0.23.
Stock Price History:
Over the past 52 weeks, DMTK has reached a high of $4.67, while it has fallen to a 52-week low of $0.62. The 50-Day Moving Average of the stock is 1.0626, while the 200-Day Moving Average is calculated to be 1.7724.
Shares Statistics:
The stock has traded on average 363.80K shares per day over the past 3-months and 220.62k shares per day over the last 10 days, according to various share statistics. A total of 34.52M shares are outstanding, with a floating share count of 30.61M. Insiders hold about 11.60% of the company’s shares, while institutions hold 16.47% stake in the company. Shares short for DMTK as of Mar 15, 2024 were 3.14M with a Short Ratio of 8.64, compared to 3.32M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.08% and a Short% of Float of 9.37%.
Earnings Estimates
Its stock is currently analyzed by 6 different market analysts. On average, analysts expect EPS of -$0.57 for the current quarter, with a high estimate of -$0.54 and a low estimate of -$0.59, while EPS last year was -$1.02. The consensus estimate for the next quarter is -$0.53, with high estimates of -$0.42 and low estimates of -$0.58.
Analysts are recommending an EPS of between -$1.62 and -$2.26 for the fiscal current year, implying an average EPS of -$1.99. EPS for the following year is -$1.62, with 5 analysts recommending between -$0.84 and -$2.23.
Revenue Estimates
6 analysts predict $3.96M in revenue for the current quarter. It ranges from a high estimate of $4.2M to a low estimate of $3.7M. As of the current estimate, DermTech Inc’s year-ago sales were $3.48M, an estimated increase of 13.90% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $4.26M, an increase of 15.40% over than the figure of $13.90% in the same quarter last year. There is a high estimate of $4.6M for the next quarter, whereas the lowest estimate is $3.9M.
A total of 6 analysts have provided revenue estimates for DMTK’s current fiscal year. The highest revenue estimate was $19.8M, while the lowest revenue estimate was $16.3M, resulting in an average revenue estimate of $17.68M. In the same quarter a year ago, actual revenue was $15.3M, up 15.60% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $21.7M in the next fiscal year. The high estimate is $24.2M and the low estimate is $19.89M. The average revenue growth estimate for next year is up 22.70% from the average revenue estimate for this year.
